Trends in the use of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and recently diagnosed colorectal, lung, or prostate cancer.
Cancer
Disease-modifying antirheumatic drugs
Drug utilization
Rheumatoid arthritis
Tumor necrosis factor inhibitors
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
04 Sep 2024
04 Sep 2024
Historique:
received:
03
06
2024
accepted:
31
08
2024
revised:
29
08
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
4
9
2024
Statut:
aheadofprint
Résumé
Biologic disease-modifying antirheumatic drugs (bDMARD) are often discontinued when a patient with rheumatoid arthritis (RA) is diagnosed with cancer. Our aim was to determine trends in bDMARD utilization in patients with RA and recently diagnosed cancer. We examined two national claims databases to identify adults with RA and recently diagnosed colorectal, lung, or prostate cancer (Optum's de-identified Clinformatics® Data Mart Database 2008-2022, and Surveillance, Epidemiology, and End Results Program (SEER) Medicare-linked 2008-2017). We determined time trends in bDMARD and tumor necrosis factor inhibitor (TNFi) prescriptions during the first 3 years after cancer with Cochram-Armitage tests and multivariable logistic regression. Cancer cohorts were analyzed separately. We included 3595 patients in all six cohorts (in Clinformatics® 503 with colorectal, 468 with lung, and 440 with prostate cancer; in SEER-Medicare 580 with colorectal, 1010 with lung, and 594 with prostate cancer). No significant increase was observed in bDMARD or TNFi utilization over time. Overall, use of bDMARD within the first 3 years of follow-up ranged from 16.7% (Clinformatics® lung cohort) to 29.7% (SEER-Medicare colorectal cohort). The major predictor of bDMARD utilization was prior use in the 3 months before cancer diagnosis (p < 0.001 for all cancers) and earlier cancer stage (p < 0.001 in colorectal and lung cancer and p = 0.05 in prostate cancer). Use of bDMARD in patients with RA and recently diagnosed common cancers has not increased since 2008. Additional evidence on the safety of bDMARD in patients with early cancer is needed to ensure appropriate management of their RA. Key Points • Use of bDMARD and TNFi in patients with RA and early colorectal, lung, or prostate cancer has been stable since 2008, with no significant increases over time. • The major determinant of receiving bDMARD after cancer diagnosis was prior treatment with bDMARD in the prior 3 months before cancer. • Patients with advanced cancer stage and distant metastases were less likely to receive bDMARD and TNFi than those at early stages of disease.
Identifiants
pubmed: 39230743
doi: 10.1007/s10067-024-07135-8
pii: 10.1007/s10067-024-07135-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR078484
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : Susan G. Komen
ID : SAC-150061
Pays : United States
Organisme : Cancer Prevention and Research Institute of Texas
ID : RP160674
Informations de copyright
© 2024. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Références
Strand V, Singh JA (2007) Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 13(Suppl 9):S237-51
pubmed: 18095787
Seror R, Lafourcade A, De Rycke Y, Pinto S, Castaneda J, Fautrel B et al (2022) Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database. RMD Open 8(2). https://doi.org/10.1136/rmdopen-2021-002139
Huss V, Bower H, Wadstrom H, Frisell T, Askling J, ARTIS group (2022) Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology (Oxford) 61(5):1810–8. https://doi.org/10.1093/rheumatology/keab570
Wadstrom H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden Study G (2017) Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med 177(11):1605–12. https://doi.org/10.1001/jamainternmed.2017.4332
doi: 10.1001/jamainternmed.2017.4332
pubmed: 28975211
pmcid: 5710271
Wetzman A, Lukas C, Gaujoux-Viala C, Mamtani R, Barnetche T, Combe B et al (2023) Risk of cancer after initiation of targeted therapies in patients with rheumatoid arthritis and a prior cancer: systematic review with meta-analysis. Arthritis Care Res (Hoboken) 75(2):260–71. https://doi.org/10.1002/acr.24784
doi: 10.1002/acr.24784
pubmed: 34549898
Raaschou P, Söderling J, Turesson C, Askling J (2018) Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: a nationwide population-based cohort study. Ann Intern Med 169(5):291–9. https://doi.org/10.7326/m17-2812
doi: 10.7326/m17-2812
pubmed: 30105374
Raaschou P, Frisell T, Askling J (2015) TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 74(12):2137–43. https://doi.org/10.1136/annrheumdis-2014-205745
doi: 10.1136/annrheumdis-2014-205745
pubmed: 25107559
Ruiz JI, Lei X, Chi-Fang W, Giordano SH, Zhao H, Rajan SS et al (2024) Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors. Breast Cancer. https://doi.org/10.1007/s12282-024-01618-x
doi: 10.1007/s12282-024-01618-x
pubmed: 39117793
Ruiz JI, Lei X, Wu CF, Zhao H, Giordano SH, Rajan SS et al (2024) Utilization of biologic disease-modifying antirheumatic therapy in patients with rheumatoid arthritis and recently diagnosed breast cancer. Arthritis Care Res (Hoboken). https://doi.org/10.1002/acr.25306
doi: 10.1002/acr.25306
pubmed: 38268474
National Cancer Instititute (2022) Division of Cancer Control and Population Sciences. SEER-Medicare Linked Data Resource. https://healthcaredelivery.cancer.gov/seermedicare/ . Accessed Oct 30 2022
Enewold L, Parsons H, Zhao L, Bott D, Rivera DR, Barrett MJ et al (2020) (2020) Updated overview of the SEER-Medicare data: enhanced content and applications. J Natl Cancer Inst Monogr 55:3–13. https://doi.org/10.1093/jncimonographs/lgz029
doi: 10.1093/jncimonographs/lgz029
Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG (1993) Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31(8):732–748
doi: 10.1097/00005650-199308000-00006
pubmed: 8336512
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–83. https://doi.org/10.1016/0021-9681(87)90171-8
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D (2007) A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 17(8):584–90. https://doi.org/10.1016/j.annepidem.2007.03.011
doi: 10.1016/j.annepidem.2007.03.011
pubmed: 17531502
Langan SM, Schmidt SA, Wing K, Ehrenstein V, Nicholls SG, Filion KB et al (2018) The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 363:k3532. https://doi.org/10.1136/bmj.k3532
doi: 10.1136/bmj.k3532
pubmed: 30429167
pmcid: 6234471
Pundole X, Zamora NV, Siddhanamatha H, Lin H, Tayar J, Hong LC et al (2020) Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer. Clin Rheumatol 39(3):787–94. https://doi.org/10.1007/s10067-019-04874-x
doi: 10.1007/s10067-019-04874-x
pubmed: 31853733
Pappas DA, Rebello S, Liu M, Schenfeld J, Li Y, Collier DH et al (2019) Therapy with biologic agents after diagnosis of solid malignancies: results from the Corrona Registry. J Rheumatol 46(11):1438–44. https://doi.org/10.3899/jrheum.171457
doi: 10.3899/jrheum.171457
pubmed: 30936285
Singh N, Grivas P, Makris UE, Suarez-Almazor ME, O’Hare AM, Barton JL (2023) Use of disease-modifying antirheumatic drugs in rheumatoid arthritis: supporting shared decision-making between patients with cancer and clinicians. ACR Open Rheumatol 5(6):305–7. https://doi.org/10.1002/acr2.11552
doi: 10.1002/acr2.11552
pubmed: 37166652
pmcid: 10267802
Bruera S, Suarez-Almazor ME (2022) The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. Front Oncol 12. https://doi.org/10.3389/fonc.2022.928390
Petrelli F, Bukovec R, Perego G, Luisa R, Luciani A, Zaniboni A et al (2020) Association of steroid use with survival in solid tumours. Eur J Cancer 141:105–114. https://doi.org/10.1016/j.ejca.2020.09.020
doi: 10.1016/j.ejca.2020.09.020
pubmed: 33130548
Pundole X, Zamora NV, Siddhanamatha H, Lin H, Tayar J, Leung CH et al (2020) Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy. Clin Rheumatol 39(10):2943–50. https://doi.org/10.1007/s10067-020-05318-7
doi: 10.1007/s10067-020-05318-7
pubmed: 32803571
pmcid: 10556973
Xie W, Xiao S, Huang Y, Sun X, Gao D, Ji L et al (2019) A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy. Rheumatology 59(5):930–9. https://doi.org/10.1093/rheumatology/kez475
doi: 10.1093/rheumatology/kez475
Waljee AK, Higgins PDR, Jensen CB, Villumsen M, Cohen-Mekelburg SA, Wallace BI et al (2020) Anti-tumour necrosis factor-alpha therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol 5(3):276–84. https://doi.org/10.1016/S2468-1253(19)30362-0
doi: 10.1016/S2468-1253(19)30362-0
pubmed: 31836320
Lopez-Olivo MA, Colmegna I, KarpesMatusevich AR, Qi SR, Zamora NV, Sharma R et al (2020) Systematic review of recommendations on the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and cancer. Arthritis Care Res 72(3):309–18. https://doi.org/10.1002/acr.23865
doi: 10.1002/acr.23865
Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K et al (2021) 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 73(7):1108–23. https://doi.org/10.1002/art.41752
doi: 10.1002/art.41752
pubmed: 34101376
Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3–18. https://doi.org/10.1136/ard-2022-223356
doi: 10.1136/ard-2022-223356
pubmed: 36357155
Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C et al (2015) European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohn’s Colitis 9(11):945–65. https://doi.org/10.1093/ecco-jcc/jjv141
doi: 10.1093/ecco-jcc/jjv141
Gordon H, Biancone L, Fiorino G, Katsanos KH, Kopylov U, Al Sulais E et al (2022) ECCO guidelines on inflammatory bowel disease and malignancies. J Crohn’s Colitis 17(6):827–54. https://doi.org/10.1093/ecco-jcc/jjac187
doi: 10.1093/ecco-jcc/jjac187